PC-904の慢性尿路感染症に対する臨床的検討

Abstract

Clinical studies on PC-904, a new broad spectrum semisynthetic penicillin with high antipseudomonas activity, were carried out as follows. PC-904 was administered to 20 cases of chronic urinary tract infections with drip infusion at the dosage of 1 to 4 g twice a day for a period of 4 to 8 days. Clinical effects were evaluated with "criteria for clinical evaluation of antimicrobial agents on U. T. I.". Clinical efficacy rate was 20% in small dosage group (1 g/time), 60% in large dosage group (more than 2 g/time), and totally 40%. In these cases, PC-904 was effective for the cases to resist against other various antibiotic therapies. But it was not effective to patients with an indwelling catheter or low vital activities. As to the relation between the MIC and the efficacy, it seems to be more effective to be treated with more than 2 g of the PC-904. No significant adverse reaction was noted, but transient elevations of GOT or GPT were observed in 2 cases.